Trimeris, Roche Withdraw Supplemental Application To Market Needle-Free Device With Antiretroviral Fuzeon

Main Category: HIV / AIDS
Also Included In: Pharma Industry / Biotech Industry
Article Date: 09 Oct 2007 - 11:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


Durham, N.C.-based pharmaceutical company Trimeris and Swiss pharmaceutical company Roche on Wednesday announced they are withdrawing a supplemental application with FDA to sell a needle-free injection device for use with the HIV antiretroviral drug Fuzeon, the Raleigh News & Observer reports (Vollmer, Raleigh News & Observer, 10/4).

Trimeris and Roche in July 2005 applied to use Bioject Medical Technologies' Biojector 2000 injection system as a needle-free injection device for use with Fuzeon, which is currently administered with a needle. Fuzeon, a fusion inhibitor, is approved to treat HIV infection in combination with other antiretrovirals. About 10% of eligible U.S. HIV-positive patients were taking Fuzeon in 2005 (Kaiser Daily HIV/AIDS Report, 11/2/05).

The companies said they decided to withdraw the application after an assessment of the clinical program, as well as a delay in FDA approval because of a request to produce more data, the AP/Houston Chronicle reports (AP/Houston Chronicle, 10/3). "While the device has shown potential benefit for some patients, we don't believe it's the ideal alternative delivery option for all treatment-experienced patients," Michelle Zupancic, a vice president at Roche, said, adding, "We continue to review other options for administering Fuzeon," (Trimeris release, 10/3).

The companies also said in a statement that they believe that "patients who are currently administering Fuzeon with the device through an existing program or clinical trial may continue to do so, provided that the precautions in the current Fuzeon label regarding use with B2000 are followed" (AP/Houston Chronicle, 10/3).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Fuzeon.


Article adapted by Medical News Today from original press release.
Visit our hiv / aids section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Trimeris, Roche Withdraw Supplemental Application To Market Needle-Free Device With Antiretroviral Fuzeon." Medical News Today. MediLexicon, Intl., 9 Oct. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/84808.php>

APA
Kaiser. (2007, October 9). "Trimeris, Roche Withdraw Supplemental Application To Market Needle-Free Device With Antiretroviral Fuzeon." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/84808.php.

Please note: If no author information is provided, the source is cited instead.




HIV / AIDS

Most Popular Articles



Follow Our HIV News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our HIV / AIDS Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »